marine drugs

IMPACT FACTOR 4.9 | Indexed in: PubMed | CITESCORE 9.6

an Open Access Journal by MDPI

Jellyfish and Polyps: Cnidarians as Sustainable Resources for Biotechnological Applications and Bioprospecting - II

Guest Editors:

Dr. Antonella Leone
National Research Council, Institute of Sciences of Food Production, Via Prov. le Lecce-Monteroni, 73100 Lecce, Italy

Dr. Gian Luigi Mariottini
Department of Earth, Environment and Life Sciences, University of Genova, Italy

Prof. Dr. Stefano Piraino
Dipartimento di Scienze e Tecnologie Biologicheed Ambientali, Università del Salento, 73100 Lecce, Italy

Deadline for manuscript submissions:
closed (31 December 2021)

Message from the Guest Editors

Sea anemones, corals, and less familiar forms of benthic polypoid cnidarians limited swimming ability, and their wide biodiversity with about 13,400 living described species make cnidarians top candidates for the development of biochemical strategies for survival (feeding, defense) and reproduction, including symbiosis or other relationships with microbes and other organisms. Venomous compounds occurring in extracts of cnidarians are viewed with particular interest for both of the aims, as well as the mitigation of their adverse effects and their possible beneficial use for humans. Furthermore, in the pharmacopeia of traditional medicine of Eastern countries, jellyfish are regarded as a treatment for disorders and diseases and represent a valuable foodstuff with health benefits, suggesting the occurrence of bioactive compounds.

This Special Issue will collect novel research papers and original reviews focusing on bioprospecting marine cnidarians and on the exploitation of their biomasses and derived compounds for biotechnological and biomedical applications, as well as active ingredients for pharmaceutical, nutraceutical, cosmetic, and cosmeceutical uses.

marine drugs

IMPACT FACTOR 4.9 | Indexed in: PubMed | CITESCORE 9.6

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker
Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
𝕏@Marine_Drugs